Overview

Where the power of nature meets the logic of science for the betterment of health.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property.... More »

Stock Quote
NASDAQ - CDXC
Price$4.17
Change (%) Stock is Down 0.03 (0.71%)
Volume137,169
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
10/16/17ChromaDex to Present at the 2017 BIO Investor Forum
IRVINE, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of science-based, proprietary health and wellness consumer products and ingredient technologies that promote health longevity announced today that its Chief Executive Officer and Co-Founder, Frank Jaksch will present at the 2017 BIO Investor Forum in San Francisco, California. Mr. Jaksch is scheduled to present on Wednesday, October 18, 2017, at 10:15 a.m. PDT. ChromaDex management will also attend... 
Printer Friendly Version
10/09/17ChromaDex Appoints Kevin Farr as New CFO
IRVINE, Calif., Oct. 09, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of science-based, proprietary health and wellness consumer products and ingredient technologies that promote health longevity, announced today that it has appointed Kevin Farr as new Chief Financial Officer, effective immediately.  Farr is joining ChromaDex from Mattel, Inc., where he was Executive Vice President and CFO since 2000.  Farr brings extensive global experience in building iconic consumer ... 
Printer Friendly Version
09/26/17ChromaDex Announces Top-line Results of its Second Human Clinical Trial
- The Study Establishes an Effective Dose Range and Validates Safety for NIAGEN® Nicotinamide Riboside Chloride in 140 Humans Over an 8-week Period - IRVINE, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of science-based, proprietary health and wellness consumer products and ingredient technologies that promote health longevity, announced today that the initial results of its second human clinical study of NIAGEN® nicotinamide riboside chloride (NR) ha... 
Printer Friendly Version
Upcoming EventsMore »

There are currently no events scheduled.

What's New
Download Documentation2017 Q2 Quarterly Report on Form 10Q
Download DocumentationSpecial Meeting – Proxy Statement
Download Documentation2017 Proxy Statement
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.